Pharmacogenetics and irinotecan therapy
Pharmacogenetics and irinotecan therapy
About this item
Full title
Author / Creator
Publisher
England: American Society of Health-System Pharmacists
Journal title
Language
English
Formats
Publication information
Publisher
England: American Society of Health-System Pharmacists
Subjects
More information
Scope and Contents
Contents
Irinotecan metabolism, irinotecan pharmacogenetic research, and the role of genetic testing before administration of the drug are reviewed.
Irinotecan is approved worldwide for the treatment of metastatic colorectal cancer but causes dose-limiting neutropenia and diarrhea. When severe, these can lead to dehydration, infection, patient discomfort...
Alternative Titles
Full title
Pharmacogenetics and irinotecan therapy
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmed_primary_17090741
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_17090741
Other Identifiers
ISSN
1079-2082
E-ISSN
1535-2900
DOI
10.2146/ajhp060155
